NAUT Nautilus Biotechnology
- 1.860
- +0.020+1.09%
- 1.860
- 0.0000.00%
Nautilus Biotechnology News
With 32% Ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Insiders Have a Lot Riding on the Company's Future
Nautilus Biotechnology Price Target Cut to $1.75/Share From $2.25 by Goldman Sachs
Nautilus Biotechnology Analyst Ratings
Goldman Sachs Downgrades Nautilus Biotechnology(NAUT.US) to Sell Rating
Goldman Sachs Downgrades Nautilus Biotechnolgy to Sell From Neutral
Nautilus Biotechnology Insiders Lose Out As Stock Sinks To US$2.47
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored With the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award
Morgan Stanley Maintains Nautilus Biotechnology(NAUT.US) With Hold Rating, Maintains Target Price $5
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
Express News | Nautilus Biotechnology Inc : Guggenheim Cuts Target Price to $4 From $6
TD Cowen Maintains Nautilus Biotechnology(NAUT.US) With Buy Rating
Nautilus Biotechnology | 10-Q: Q3 2024 Earnings Report
Nautilus Biotechnology | 8-K: Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript Summary
Nautilus Biotechnology 3Q Loss $16.4M >NAUT
Nautilus Biotechnology 3Q Loss/Shr 13c >NAUT
Nautilus Biotechnology Reported Q3 Cash Balance Of $221.2M
Nautilus Biotechnology Q3 2024 GAAP EPS $(0.13) Beats $(0.17) Estimate
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
Earnings Preview: NAUT to Report Financial Results Pre-market on October 29
$Nautilus Biotechnology(NAUT.US)$ is scheduled to release its financial results pre-market on October 29 ET. Earnings PreviewAnalysts estimate $Nautilus Biotechnology(NAUT.US)$ to post revenue of USD0
No Data